Cargando…

Cerebrospinal Fluid α-Synuclein Species in Cognitive and Movements Disorders

Total CSF α-synuclein (t-α-syn), phosphorylated α-syn (pS129-α-syn) and α-syn oligomers (o-α-syn) have been studied as candidate biomarkers for synucleinopathies, with suboptimal specificity and sensitivity in the differentiation from healthy controls. Studies of α-syn species in patients with other...

Descripción completa

Detalles Bibliográficos
Autores principales:	Constantinides, Vasilios C., Majbour, Nour K., Paraskevas, George P., Abdi, Ilham, Safieh-Garabedian, Bared, Stefanis, Leonidas, El-Agnaf, Omar M., Kapaki, Elisabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830324/ https://www.ncbi.nlm.nih.gov/pubmed/33477387 http://dx.doi.org/10.3390/brainsci11010119

Ejemplares similares

Cerebrospinal Fluid Biomarkers in iNPH: A Narrative Review
por: Pyrgelis, Efstratios-Stylianos, et al.
Publicado: (2022)

Disease-Associated α-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage
por: Majbour, Nour, et al.
Publicado: (2022)

Corticobasal degeneration and corticobasal syndrome: A review
por: Constantinides, Vasilios C., et al.
Publicado: (2019)

Structural and Biophysical Characterization of Stable Alpha-Synuclein Oligomers
por: Vaikath, Nishant, et al.
Publicado: (2022)

α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2018)

Assessment of Aggregated and Exosome-Associated α-Synuclein in Brain Tissue and Cerebrospinal Fluid Using Specific Immunoassays
por: Anagnostou, Dimitrios, et al.
Publicado: (2023)

Cerebrospinal Fluid Biomarker Profile in TDP-43-Related Genetic Frontotemporal Dementia
por: Kapaki, Elisabeth, et al.
Publicado: (2022)

Cerebrospinal fluid biomarkers and apolipoprotein E genotype in cerebral amyloid angiopathy. A narrative review
por: Theodorou, Aikaterini, et al.
Publicado: (2021)

Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers
por: Aasly, Jan O., et al.
Publicado: (2014)

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2014)

Preanalytical Stability of CSF Total and Oligomeric Alpha-Synuclein
por: Abdi, Ilham Y., et al.
Publicado: (2021)

Callosal Angle Sub-Score of the Radscale in Patients with Idiopathic Normal Pressure Hydrocephalus Is Associated with Positive Tap Test Response
por: Pyrgelis, Efstratios-Stylianos, et al.
Publicado: (2022)

CSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer’s Disease and Frontotemporal Dementias
por: Constantinides, Vasilios C., et al.
Publicado: (2023)

Alzheimer’s Disease CSF Biomarkers as Possible Indicators of Tap-Test Response in Idiopathic Normal Pressure Hydrocephalus
por: Pyrgelis, Efstratios-Stylianos, et al.
Publicado: (2023)

Neuronal and Neuroaxonal Damage Cerebrospinal Fluid Biomarkers in Autoimmune Encephalitis Associated or Not with the Presence of Tumor
por: Vakrakou, Aigli G., et al.
Publicado: (2022)

Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
por: Majbour, Nour K., et al.
Publicado: (2016)

Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease in the Era of Disease-Modifying Treatments
por: Paraskevas, George P., et al.
Publicado: (2021)

Imaging Markers for Normal Pressure Hydrocephalus: An Overview
por: Pyrgelis, Efstratios-Stylianos, et al.
Publicado: (2023)

Ultrasonication-based rapid amplification of α-synuclein aggregates in cerebrospinal fluid
por: Kakuda, Keita, et al.
Publicado: (2019)

Genotyping and Plasma/Cerebrospinal Fluid Profiling of a Cohort of Frontotemporal Dementia–Amyotrophic Lateral Sclerosis Patients
por: Bourbouli, Mara, et al.
Publicado: (2021)

Application of the AT(N) and Other CSF Classification Systems in Behavioral Variant Frontotemporal Dementia
por: Constantinides, Vasilios C., et al.
Publicado: (2023)

Mixed Small Vessel Disease in a Patient with Dementia with Lewy Bodies
por: Paraskevas, George P., et al.
Publicado: (2019)

A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein
por: Landeck, Natalie, et al.
Publicado: (2016)

Cerebrospinal Fluid Lysosomal Enzymes and Alpha-Synuclein in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity
por: Gupta, Vijay, et al.
Publicado: (2020)

Diffuse glioma manifesting as normal pressure hydrocephalus: A potential pitfall in diagnosis-a case report
por: Breza, Marianthi, et al.
Publicado: (2021)

Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice
por: Karampetsou, Mantia, et al.
Publicado: (2017)

A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid(42) and DJ-1 in Human Cerebrospinal Fluid
por: Kruse, Niels, et al.
Publicado: (2016)

Thyroid Autoantibodies in the Cerebrospinal Fluid of Subjects with and without Thyroid Disease: Implications for Hashimoto's Encephalopathy
por: Ilias, Ioannis, et al.
Publicado: (2015)

CSF or serum neurofilament light added to α‐Synuclein panel discriminates Parkinson's from controls
por: Oosterveld, Linda P., et al.
Publicado: (2019)

Novel PANK2 mutation in the first Greek compound heterozygote patient with pantothenate-kinase-associated neurodegeneration
por: Paraskevas, George P, et al.
Publicado: (2017)

The Diagnostic Value of CSF α-Synuclein in the Differential Diagnosis of Dementia with Lewy Bodies vs. Normal Subjects and Patients with Alzheimer’s Disease
por: Kapaki, Elisabeth, et al.
Publicado: (2013)

Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease
por: Majbour, Nour K., et al.
Publicado: (2017)

α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity
por: Ghanem, Simona S., et al.
Publicado: (2022)

Investigating the presence of doubly phosphorylated α‐synuclein at tyrosine 125 and serine 129 in idiopathic Lewy body diseases
por: Fayyad, Muneera, et al.
Publicado: (2020)

Recognizing Atypical Presentations of Alzheimer’s Disease: The Importance of CSF Biomarkers in Clinical Practice
por: Paraskevas, George P., et al.
Publicado: (2022)

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

Antibody‐based methods for the measurement of α‐synuclein concentration in human cerebrospinal fluid – method comparison and round robin study
por: Mollenhauer, Brit, et al.
Publicado: (2018)

CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriers
por: Majbour, Nour K., et al.
Publicado: (2020)

Prion-like α-synuclein pathology in the brain of infants with Krabbe disease
por: Hatton, Christopher, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i5nh232ag66dacc4b8ogj2spfj